Emavusertib Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated: June 2, 2026

The clinical evidence base for Emavusertib comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Myelodysplastic Syndromes. Most recent publication: Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication., Int J Mol Sci, 2023.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS, Loo S · Int J Mol Sci · 2023
PubMed: PMID 36902217 · NCT05564390 · Myelodysplastic Syndromes

Publications by year

2023–2023: 1 publications.

2023

Publications by indication

Myelodysplastic Syndromes (1)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Int J Mol Sci · 2023 · PMID 36902217 · NCT05564390

Publications by journal

Int J Mol Sci1 paper

All Emavusertib publications (1)

2023 (1 paper)

Targeting Measurable Residual Disease (MRD) in Acute Myeloid Leukemia (AML): Moving beyond Prognostication.
Tiong IS, Loo S · Int J Mol Sci · 2023 · Derived
PubMed: PMID 36902217 · NCT05564390 · Myelodysplastic Syndromes

Sources and methodology

Publications: ctgov.study_references (PubMed PMIDs auto-attached by ClinicalTrials.gov to each trial), reference types RESULT, DERIVED, and BACKGROUND.
Per-arm outcome values: ctgov.outcome_measurements joined to ctgov.design_outcomes where outcome_type = 'PRIMARY', restricted to phase PHASE3 and PHASE2/PHASE3.
Publication metadata (title, journal, year, authors): PubMed E-utilities efetch.fcgi
Data freshness: Tue, 02 Jun 2026 17:25:30 GMT.

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).